 |
市场调查报告书
商品编码
1621655
血癌诊断市场机会、成长动力、产业趋势分析与预测 2024 - 2032Blood Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
||||||
2023 年全球血癌诊断市场价值为 124 亿美元，预计 2024 年至 2032 年复合年增长率为 6.8%。淋巴系统。市场成长的主要驱动力之一是全球血癌发生率的上升。随着越来越多的人接受白血病、淋巴瘤和骨髓瘤等疾病的诊断，对有效诊断工具的需求激增。盛行率的增加可归因于多种因素，包括人口老化、遗传倾向和环境影响。
血癌诊断市场按测试类型细分，包括分子测试、血液检查、影像测试和活检。血液检测占据了市场的很大一部分，到 2023 年约占 47 亿美元。此外，该市场按最终用途分类，包括医院、诊断实验室、影像中心和癌症研究机构。到 2032 年，医院领域预计将达到 90 亿美元。
对尖端诊断设备的大量投资以及对早期检测和个人化治疗策略的高度重视推动了这一趋势。医院的综合医疗保健系统促进了高效的患者管理和跨多个部门的协调护理，进一步巩固了其在血癌诊断中的关键作用。在美国，到 2032 年，血癌诊断市场预计将成长至约 94 亿美元。这种积极主动的方法提高了患者的生存率，同时推动了对诊断测试和技术的需求，从而促进了区域市场的成长。
| 市场范围 | |
|---|---|
| 开始年份 | 2023年 |
| 预测年份 | 2024-2032 |
| 起始值 | 124 亿美元 |
| 预测值 | 222亿美元 |
| 复合年增长率 | 6.8% |
此外，用于加强支持血癌诊断和治疗的基础设施的公共和私人投资都对该行业的收入成长做出了重大贡献。
目录
第 1 章：方法与范围
第 2 章：执行摘要
第 3 章：产业洞察
- 产业生态系统分析
- 产业影响力
- 成长动力
- 血癌盛行率上升
- 癌症诊断技术的进步
- 提高认识和早期筛检计划
- 产业陷阱与挑战
- 先进诊断的高成本
- 严格的监管场景
- 成长动力
- 成长潜力分析
- 监管环境
- 技术景观
- 核心技术
- 邻近技术
- 未来市场趋势
- 差距分析
- 波特的分析
- 杵分析
第 4 章：竞争格局
- 介绍
- 公司市占率分析
- 公司矩阵分析
- 主要市场参与者的竞争分析
- 竞争定位矩阵
- 战略仪表板
第 5 章：市场估计与预测：按产品分类，2021 - 2032 年
- 主要趋势
- 仪器仪表
- 检测试剂盒和试剂
第 6 章：市场估计与预测：按测试类型，2021 - 2032 年
- 主要趋势
- 血液检查
- 影像学检查
- 活检
- 分子测试
第 7 章：市场估计与预测：按癌症类型，2021 - 2032 年
- 主要趋势
- 白血病
- 淋巴瘤
- 骨髓瘤
第 8 章：市场估计与预测：按最终用途，2021 - 2032 年
- 主要趋势
- 医院
- 诊断实验室
- 诊断影像中心
- 癌症研究机构
第 9 章：市场估计与预测：按地区，2021 - 2032
- 主要趋势
- 北美洲
- 我们
- 加拿大
- 欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
第 10 章：公司简介
- Abbott Laboratories
- Alercell, Inc.
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- F. Hoffmann-La Roche Ltd
- GE HealthCare Technologies Inc.
- HORIBA, Ltd.
- Illumina, Inc.
- Invivoscribe, Inc.
- QIAGEN NV
- Sysmex Corporation
- Thermo Fisher Scientific Inc.
The Global Blood Cancer Diagnostics Market was valued at USD 12.4 billion in 2023 and is projected to grow at a CAGR of 6.8% between 2024 and 2032. Blood cancer diagnostics encompasses various tests and procedures designed to diagnose, detect, and monitor cancers affecting the bone marrow, blood, and lymphatic system. One of the primary drivers of market growth is the rising incidence of blood cancers worldwide. As more individuals receive diagnoses for conditions like leukemia, lymphoma, and myeloma, the demand for effective diagnostic tools has surged. This increase in prevalence can be attributed to several factors, including an aging population, genetic predispositions, and environmental influences.
The blood cancer diagnostics market is segmented by test type, including molecular tests, blood tests, imaging tests, and biopsies. Blood tests represent a substantial portion of the market, accounting for around USD 4.7 billion in 2023. These tests are a cornerstone in the early detection and monitoring of blood cancers due to their affordability and quick turnaround time, making them a favored option among healthcare professionals. Additionally, the market is categorized by end-use, comprising hospitals, diagnostic laboratories, imaging centers, and cancer research institutes. The hospital segment is expected to reach USD 9 billion by 2032. Hospitals are increasingly incorporating advanced diagnostic technologies to enhance the precision and speed of blood cancer detection.
This trend is fueled by significant investments in cutting-edge diagnostic equipment and a strong focus on early detection and personalized treatment strategies. The integrated healthcare systems found in hospitals facilitate efficient patient management and coordinated care across multiple departments, further solidifying their crucial role in blood cancer diagnostics. In the United States, the blood cancer diagnostics market is anticipated to grow to approximately USD 9.4 billion by 2032. There is a notable emphasis on early detection and prevention of blood cancers, with healthcare providers and government entities advocating for routine screenings and early diagnoses. This proactive approach improves patient survival rates while driving demand for diagnostic tests and technologies, boosting the regional market growth.
| Market Scope | |
|---|---|
| Start Year | 2023 |
| Forecast Year | 2024-2032 |
| Start Value | $12.4 Billion |
| Forecast Value | $22.2 Billion |
| CAGR | 6.8% |
Furthermore, both public and private investments to enhance the infrastructure to support blood cancer diagnosis and treatment contribute significantly to revenue growth in this sector.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of blood cancer
- 3.2.1.2 Advancements in cancer diagnostic technologies
- 3.2.1.3 Growing awareness and early screening programs
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of advanced diagnostics
- 3.2.2.2 Stringent regulatory scenario
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technology landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTLE analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Instruments
- 5.3 Assay kits and reagents
Chapter 6 Market Estimates and Forecast, By Test Type, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Blood tests
- 6.3 Imaging tests
- 6.4 Biopsy
- 6.5 Molecular tests
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Leukemia
- 7.3 Lymphoma
- 7.4 Myeloma
Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Diagnostic laboratories
- 8.4 Diagnostic imaging centers
- 8.5 Cancer research institutes
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 Alercell, Inc.
- 10.3 Becton, Dickinson and Company
- 10.4 Bio-Rad Laboratories, Inc.
- 10.5 Bio-Techne Corporation
- 10.6 Danaher Corporation
- 10.7 F. Hoffmann-La Roche Ltd
- 10.8 GE HealthCare Technologies Inc.
- 10.9 HORIBA, Ltd.
- 10.10 Illumina, Inc.
- 10.11 Invivoscribe, Inc.
- 10.12 QIAGEN N.V.
- 10.13 Sysmex Corporation
- 10.14 Thermo Fisher Scientific Inc.
